VRTX
Vertex Pharmaceuticals Inc
508.30$
-1.5%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 66.2% | 54.3% | 60.9% | 70.0% | 59.3% | 58.0% | 69.2% | 71.2% | 72.9% | 62.2% | 42.6% | 42.8% | |
| 26.8% | 28.6% | 40.9% | 47.0% | 42.4% | 37.4% | 51.0% | 50.6% | 57.9% | 45.6% | 20.3% | 19.5% | |
| 59.4% | 41.7% | 49.6% | 58.9% | 50.7% | 45.8% | 56.7% | 56.0% | 59.4% | 49.4% | 27.1% | 25.3% | |
| 3.9% | 7.1% | 6.9% | 7.9% | 6.6% | 7.6% | 7.5% | 8.5% | 7.9% | 6.9% | 7.1% | 7.9% | |
| 1.3% | 2.2% | 2.7% | 3.2% | 2.0% | 2.0% | 2.4% | 2.6% | 2.5% | 3.3% | 5.3% | 6.5% | |
| 30.6% | 27.9% | 24.1% | 22.3% | 13.0% | 10.0% | 8.2% | 8.1% | 8.0% | – | – | – | |
| 1.7% | 2.0% | 1.7% | 1.4% | 0.8% | 12.0% | 8.5% | 7.5% | 6.0% | 4.8% | 4.8% | 4.2% | |
| 1.2% | 11.4% | 9.8% | 0.8% | 0.8% | 4.8% | 3.4% | 3.0% | 3.3% | 3.7% | 3.7% | 1.6% | |
| 53.0% | 56.2% | 53.8% | 42.4% | 29.0% | 26.8% | 26.1% | 24.8% | 23.3% | 22.7% | 27.2% | 28.6% | |
| 15.8% | 20.3% | 0.3% | 22.8% | 11.5% | 16.0% | 16.0% | 15.9% | 15.1% | 15.6% | 15.8% | 14.8% | |
| 1.4% | 3.5% | 11.0% | 0.6% | 0.2% | 0.5% | 0.4% | 0.6% | 0.5% | 0.4% | 0.4% | 0.3% | |
| 3.0% | 3.0% | 2.1% | 2.1% | 1.8% | 1.1% | 1.3% | 1.5% | 1.7% | 1.6% | 1.8% | 1.8% | |
| 32.3% | 27.9% | 16.8% | 15.9% | 9.0% | – | – | – | – | – | – | – | |
| 46.0% | 43.8% | 46.2% | 57.6% | 71.0% | 73.2% | 73.9% | 75.2% | 76.7% | 77.3% | 72.8% | 71.4% | |
| -201.4% | -210.7% | -185.7% | -144.4% | -47.9% | -22.3% | 7.3% | 23.8% | 35.9% | 44.6% | 42.6% | 51.9% | |
| 10.1% | 9.7% | 8.5% | 7.1% | 4.1% | 3.1% | 2.2% | 1.9% | 1.4% | 1.1% | 1.1% | 1.0% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.